185 related articles for article (PubMed ID: 35711955)
1. Synthesis, Characterization and Antitumor Mechanism Investigation of Heterometallic Ru(Ⅱ)-Re(Ⅰ) Complexes.
Ma X; Lu J; Yang P; Huang B; Li R; Ye R
Front Chem; 2022; 10():890925. PubMed ID: 35711955
[TBL] [Abstract][Full Text] [Related]
2. Heteronuclear Ru(II)-Re(I) complexes as potential photodynamic anticancer agents with anti-metastatic and anti-angiogenic activities.
Ma XR; Lu JJ; Huang B; Lu XY; Li RT; Ye RR
J Inorg Biochem; 2023 Mar; 240():112090. PubMed ID: 36543061
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, characterization and antitumor mechanism investigation of ruthenium(II) polypyridyl complexes with artesunate moiety.
Chen BC; Lu JJ; Jiang N; Ma XR; Li RT; Ye RR
J Biol Inorg Chem; 2021 Dec; 26(8):909-918. PubMed ID: 34545414
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, characterization, molecular docking, RNA-sequence and anticancer efficacy evaluation in vitro of ruthenium(II) complexes on B16 cells.
Huang C; Zhang H; Yang Y; Liu H; Chen J; Wang Y; Liang L; Hu H; Liu Y
J Inorg Biochem; 2023 Oct; 247():112329. PubMed ID: 37478780
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of new ruthenium polypyridyl complexes with potent antitumor activity in vitro.
Jiang GB; Zhang WY; He M; Gu YY; Bai L; Wang YJ; Yi QY; Du F
Spectrochim Acta A Mol Biomol Spectrosc; 2019 Sep; 220():117132. PubMed ID: 31146211
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, RNA-sequence and evaluation of anticancer efficacy of ruthenium(II) polypyridyl complexes toward HepG2 cells.
Hu H; Zhang H; Zhong R; Yang Y; Huang C; Chen J; Liang L; Chen Y; Liu Y
J Inorg Biochem; 2023 Jul; 244():112230. PubMed ID: 37084581
[TBL] [Abstract][Full Text] [Related]
7. Systematic evaluation of the antitumor activity of three ruthenium polypyridyl complexes.
Jiang GB; Zhang WY; He M; Gu YY; Bai L; Wang YJ; Yi QY; Du F
J Inorg Biochem; 2021 Dec; 225():111616. PubMed ID: 34555601
[TBL] [Abstract][Full Text] [Related]
8. Development of four ruthenium polypyridyl complexes as antitumor agents: Design, biological evaluation and mechanism investigation.
Jiang GB; Zhang WY; He M; Gu YY; Bai L; Wang YJ; Yi QY; Du F
J Inorg Biochem; 2020 Jul; 208():111104. PubMed ID: 32485635
[TBL] [Abstract][Full Text] [Related]
9. Anticancer activity of ruthenium(II) plumbagin complexes with polypyridyl as ancillary ligands via inhibiting energy metabolism and GADD45A-mediated cell cycle arrest.
Li YL; Zhu XM; Chen NF; Chen ST; Yang Y; Liang H; Chen ZF
Eur J Med Chem; 2022 Jun; 236():114312. PubMed ID: 35421660
[TBL] [Abstract][Full Text] [Related]
10. Novel heterobimetallic Ir(III)-Re(I) complexes: design, synthesis and antitumor mechanism investigation.
Lu JJ; Ma XR; Xie K; Yang PX; Li RT; Ye RR
Dalton Trans; 2022 May; 51(20):7907-7917. PubMed ID: 35535974
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, characterization, and anticancer activity of ruthenium(II)-β-carboline complex.
Chen Y; Qin MY; Wu JH; Wang L; Chao H; Ji LN; Xu AL
Eur J Med Chem; 2013; 70():120-9. PubMed ID: 24141202
[TBL] [Abstract][Full Text] [Related]
12. Cyclometalated Ru(II) β-carboline complexes induce cell cycle arrest and apoptosis in human HeLa cervical cancer cells via suppressing ERK and Akt signaling.
Chen J; Deng Y; Wang J; Chen S; Peng F; He X; Liu M; Luo H; Zhang J; Chen L
J Biol Inorg Chem; 2021 Oct; 26(7):793-808. PubMed ID: 34459988
[TBL] [Abstract][Full Text] [Related]
13. Lysosome-targeted ruthenium(II) complexes induce both apoptosis and autophagy in HeLa cells.
Pan NL; Liao JX; Huang MY; Zhang YQ; Chen JX; Zhang ZW; Yang ZX; Long XE; Wu XT; Sun J
J Inorg Biochem; 2022 Apr; 229():111729. PubMed ID: 35066350
[TBL] [Abstract][Full Text] [Related]
14. Ruthenium(II) complexes as mitochondrial inhibitors of topoisomerase induced A549 cell apoptosis.
Tang H; Guo X; Yu W; Gao J; Zhu X; Huang Z; Ou W; Zhang H; Chen L; Chen J
J Inorg Biochem; 2023 Sep; 246():112295. PubMed ID: 37348172
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and characterization of polypyridine ruthenium(II) complexes and anticancer efficacy studies in vivo and in vitro.
Liang L; Wu X; Shi C; Wen H; Wu S; Chen J; Huang C; Wang Y; Liu Y
J Inorg Biochem; 2022 Nov; 236():111963. PubMed ID: 35988387
[TBL] [Abstract][Full Text] [Related]
16. Protein binding and anticancer activity studies of ruthenium(II) polypyridyl complexes toward BEL-7402 cells.
Lai SH; Li W; Yao JH; Han BJ; Jiang GB; Zhang C; Zeng CC; Liu YJ
J Photochem Photobiol B; 2016 May; 158():39-48. PubMed ID: 26945645
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization and anticancer effect of the ruthenium (II) polypyridyl complexes on HepG2 cells.
Wan D; Lai SH; Yang HH; Tang B; Zhang C; Yin H; Zeng CC; Liu YJ
J Photochem Photobiol B; 2016 Dec; 165():246-255. PubMed ID: 27816647
[TBL] [Abstract][Full Text] [Related]
18. Novel cyclometalated Ru(II) complexes containing isoquinoline ligands: Synthesis, characterization, cellular uptake and in vitro cytotoxicity.
Chen J; Wang J; Deng Y; Li B; Li C; Lin Y; Yang D; Zhang H; Chen L; Wang T
Eur J Med Chem; 2020 Oct; 203():112562. PubMed ID: 32698112
[TBL] [Abstract][Full Text] [Related]
19. The induction of mitochondria-mediated apoptosis in cancer cells by ruthenium(II) asymmetric complexes.
Qian C; Wang JQ; Song CL; Wang LL; Ji LN; Chao H
Metallomics; 2013 Jun; 5(7):844-54. PubMed ID: 23483103
[TBL] [Abstract][Full Text] [Related]
20. Ruthenium(II)-Polypyridyl Compounds with π-Extended Nitrogen Donor Ligands Induce Apoptosis in Human Lung Adenocarcinoma (A549) Cells by Triggering Caspase-3/7 Pathway.
Peña B; Saha S; Barhoumi R; Burghardt RC; Dunbar KR
Inorg Chem; 2018 Oct; 57(20):12777-12786. PubMed ID: 30239197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
